AI CuratorAI-generated
Research summary · AI summary · not yet reviewedSubjects not reportedNot reportedPublished in a peer-reviewed journal
Associations of PML and Cryptococcal Disease with Natalizumab and Fingolimod in Animal/Cell Studies
Associations between PML linked to Natalizumab and increased cases of Cryptococcal disease related to Fingolimod were noted, occurring more frequently than previously expected based on general trends.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Not graded
- Outcome
- Not reported
Why it matters
This finding highlights the potential risks associated with these disease-modifying therapies in multiple sclerosis, suggesting a need for careful monitoring of infections in patients receiving these treatments.
What this does not prove
The specific effects of Natalizumab and Fingolimod on infection vulnerability remain unidentified.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-21
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceProportionate and disproportionate reporting of different infectious complications of disease modifying therapy in multiple sclerosis. ↗DOI: 10.1186/s42466-026-00544-x
Supporting passages (5)
publication datePublication date: 2026-10-21
interventionINTRODUCTION: Progessive multifocal leukoencephalopathy (PML) is a complication of immunoincompetence due to disease or immunosuppressive therapy and in particular due to disease modifying therapy (DMT) in multiple sclerosis.
findingsRESULTS: The associations of PML/Natalizumab and Cryptococcal disease/Fingolimod were reported significantly more frequently than expected from the general reporting pattern as extracted from the PCA.
limitationsCONCLUSION: These associations are candidates for which specific effects of Natalizumab and Fingolimod should be identified that increase vulnerability to respective infections.
peer reviewedPublication types: Journal Article
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.